Lexology August 29, 2023
While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations and the first 10 drugs covered under the IRA, constitutional challenges to the IRA’s drug-pricing provisions are mounting, and Congress is considering several new bills that seek to ban specific PBM practices and target certain types of conduct by drug manufacturers. In this alert, we examine these recent developments and outline some takeaways on where things stand on drug pricing in 2023.1
The Inflation Reduction Act Faces Legal Challenges
The Inflation Reduction Act (IRA) contains several provisions aimed at lowering drug prices. The IRA empowers the Department of...
Today's Sponsors
Today's Sponsor